Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OneSource Specialty PharmaNSE:ONESOURCE -2.14%8 EV-to-EBIT is 315.40 as of Aug. 27, 2026, which is 121% above its 10-year median of 142.46. GuruFocus rates NSE:ONESOURCE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 380 Biotechnology companies, OneSource Specialty Pharma ranks worse than 97.37% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
OneSource Specialty Pharma's Enterprise Value for the quarter that ended in Jun. 2026 was ₹188,914 Mil.
OneSource Specialty Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹582 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OneSource Specialty Pharma EV-to-EBIT Related Terms
OneSource Specialty Pharma EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ONESOURCE vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, OneSource Specialty Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OneSource Specialty Pharma EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OneSource Specialty Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where OneSource Specialty Pharma's EV-to-EBIT falls into.
OneSource Specialty Pharma's current Enterprise Value is ₹183,715 Mil.
OneSource Specialty Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹582 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OneSource Specialty Pharma (NSE:ONESOURCE) has a EV-to-EBIT of 315.40 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OneSource Specialty Pharma and its competitors. This is 121% above median its historical median of 142.46. According to the industry distribution chart, OneSource Specialty Pharma ranks #370 out of 380 companies in the Biotechnology industry, placing it in the top 97.4%.
Is OneSource Specialty Pharma's EV-to-EBIT too high?
OneSource Specialty Pharma's current EV-to-EBIT of 315.40 is 121% above median its 10-year median of 142.46. The Biotechnology industry median EV-to-EBIT is 15.86. OneSource Specialty Pharma's value of 315.40 is 1889.3% above this industry median. Based on the distribution chart, OneSource Specialty Pharma ranks #370 out of 380 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OneSource Specialty Pharma ranks #370 out of 380 companies for EV-to-EBIT. This places OneSource Specialty Pharma in the lower half of its industry. The industry median EV-to-EBIT is 15.86. OneSource Specialty Pharma's value of 315.40 is 1889.3% above this benchmark. While the company's 10-year median is 142.46 vs. the industry median of 15.86, OneSource Specialty Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.86, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OneSource Specialty Pharma's current EV-to-EBIT of 315.40 is 1889.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OneSource Specialty Pharma and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OneSource Specialty Pharma's current EV-to-EBIT is 315.40, which is 121% above median its own 10-year median of 142.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (NSE:ONESOURCE) has a current EV-to-EBIT of 315.40. The current EV-to-EBIT is 315.40, which is 121% above median its 10-year median of 142.46 and 1889.3% above the Biotechnology industry median of 15.86. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For OneSource Specialty Pharma (NSE:ONESOURCE), the current EV-to-EBIT is 315.40 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score
Get the complete analysis for NSE:ONESOURCE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONESOURCE has been successfully added to your 
